Clinical Characteristics, Outcomes, and Risk Factors for Patients with Diffuse Large B-Cell Lymphoma and Development of Nomogram to Identify High-Risk Patients

Table 3

Clinical characteristics of patients with DLBCL (IPI 4-5, n = 161).

Characteristics	Nonhigh-risk^a, n (%)	High-risk^a, n (%)	value^b
Total	117	44
Gender
Male	51 (43.6)	20 (45.5)	0.832
Female	66 (56.4)	24 (54.5)
Age
≤60	56 (47.9)	6 (13.6)	<0.001
>60	61 (52.1)	38 (86.4)
COO
GCB	56 (47.9)	15 (34.1)	0.117
Non-GCB	61 (52.1)	29 (65.9)
Ki-67 (%)
≥90	26 (22.2)	9 (20.5)	0.809
<90	91 (77.8)	35 (79.5)
B symptoms
Presence	87 (74.4)	38 (86.4)	0.103
Absence	30 (25.6)	6 (13.6)
ECOG
0-1	27 (23.1)	0 (0)	<0.001
>1	90 (79.9)	44 (100)
Bulky disease
Presence	15 (12.8)	3 (6.8)	0.403
Absence	102 (87.2)	41 (93.2)
Ann Arbor
I-II	1 (0.8)	0 (0)	1
III-IV	116 (99.2)	44 (100)
No. of extranodal sites
0-1	78 (66.7)	23 (52.3)	0.092
>1	39 (33.3)	21 (47.7)
BM involvement
Presence	18(15.4)	25 (56.8)	<0.001
Absence	99 (84.6)	19 (43.2)
CNS involvement
Presence	10 (8.5)	8 (18.2)	0.084
Absence	107 (91.5)	36 (91.8)
LDH
Elevated	95 (81.2)	36 (81.8)	0.928
Normal	22 (18.8)	8 (18.2)
Alb
Low	59 (50.5)	43 (97.7)	<0.001
Normal	58 (49.5)	1 (2.3)
LMR
Low^c	57 (48.7)	35 (79.5)	<0.001
High	60 (51.3)	9 (20.5)
D-dimer
>0.87	91 (77.8)	32 (72.7)	0.501
≤0.87	26 (22.2)	12 (27.3)
HBsAg
Positive	11 (9.4)	2 (4.5)	0.517
Negative	106 (90.6)	42 (95.5)

LMR, lymphocyte-monocyte ratio; BM, bone marrow; CNS, central nervous system; COO, cell of origin; ECOG, Eastern Cooperative Oncology Group; ^ausing our new model to distinguish prognostic subgroups. ^bnonhigh-risk vs. high-risk patients, value was calculated by the Pearson Chi-square test or Fisher’s exact test, and is regarded significant. ^c<2.5.